Chordate Medical Holding AB (OSTO:CMH) Interest Expense: kr-0.01 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
View Full Analysis

What is Chordate Medical Holding AB Interest Expense?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 Interest Expense is kr-0.01 Mil as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chordate Medical Holding AB's interest expense for the three months ended in Jun. 2025 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2025 was kr-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chordate Medical Holding AB's Operating Income for the three months ended in Jun. 2025 was kr -5.19 Mil. Chordate Medical Holding AB's Interest Expense for the three months ended in Jun. 2025 was kr 0.00 Mil. Chordate Medical Holding AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chordate Medical Holding AB  (OSTO:CMH) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chordate Medical Holding AB's Interest Expense for the three months ended in Jun. 2025 was kr0.00 Mil. Its Operating Income for the three months ended in Jun. 2025 was kr-5.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2025 was kr0.00 Mil.

Chordate Medical Holding AB's Interest Coverage for the quarter that ended in Jun. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Chordate Medical Holding AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB Interest Expense Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.34 -0.03 0.00 -0.01 -0.01

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.02 0.00
OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-0.01 Mil mean?
Chordate Medical Holding AB (OSTO:CMH) has a Interest Expense of kr-0.01 Mil as of Jun. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's Interest Expense too high?
Chordate Medical Holding AB's current Interest Expense is kr-0.01 Mil. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's Interest Expense compare to ABT and SYK?
Chordate Medical Holding AB's Interest Expense of kr-0.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chordate Medical Holding AB and its competitors. Chordate Medical Holding AB's current Interest Expense is kr-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current Interest Expense of kr-0.01 Mil. The current Interest Expense is kr-0.01 Mil. Chordate Medical Holding AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current Interest Expense is kr-0.01 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price